Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19? - 12/08/21
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Highlights |
• | At present, the association between metformin use and mortality in DM patients with COVID-19 remains uncertain. |
• | Our data have revealed more favourable survival in patients not taking DM drugs compared with patients taking DM drugs other than metformin. |
• | This study showed no definite association between metformin use and clinical outcomes, including survival. |
• | Further studies are needed to determine whether the use of metformin may have favourable or unfavourable effects in DM patients with COVID-19. |
Abstract |
Aim |
Previous studies have reported inconsistent results regarding the association between metformin use and clinical outcomes in diabetes mellitus (DM) patients with coronavirus disease 2019 (COVID-19). This study aimed to evaluate the association between metformin use and clinical outcomes in DM patients with COVID-19.
Methods |
This retrospective study was based on claims data. All diseases, including COVID-19, were defined using International Classification of Diseases 10th Revision (ICD-10) codes. Patients were divided into three groups depending on metformin use: CON (those not taking DM medication); N-MFOM (those taking DM medications other than metformin); and MFOM (those taking metformin for DM). Ultimately, 1865 patients were included; CON, N-MFOM and MFOM groups comprised 1301, 95 and 469 patients, respectively.
Results |
Kaplan–Meier analyses showed that MFOM patients had poorer survival rates than those in the CON group, but there were no significant differences in survival rates between MFOM and N-MFOM groups. Multivariate Cox regression analyses revealed more favourable survival in CON than in N-MFOM patients, but there was no statistically significant difference in MFOM vs the other groups. Also, there were no significant differences in rates of use of inotropes, extracorporeal membrane oxygenation, conventional oxygen therapy, high-flow nasal cannulas or mechanical ventilators, nor in the rates of acute kidney injury or cardiac events across all study groups.
Conclusion |
No definite association could be found between metformin use and clinical outcomes, including survival. However, given the disproportionate participant numbers in our groups and small number of events, further studies are needed to determine whether the use of metformin has favourable or unfavourable effects in DM patients with COVID-19.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Clinical outcome, Coronavirus disease, COVID-19, Diabetes mellitus, Metformin
Mappa
Vol 47 - N° 4
Articolo 101208- luglio 2021 Ritorno al numero
Articolo precedente
- Glyburide therapy for gestational diabetes: Glycaemic control, maternal hypoglycaemia, and treatment failure
- Hélène Affres, Marie-Victoire Senat, Alexandra Letourneau, Philippe Deruelle, Magali Coustols-Valat, Hanane Bouchghoul, Jean Bouyer
- Association of diabetes and outcomes in patients with COVID-19: Propensity score-matched analyses from a French retrospective cohort
- Willy Sutter, Baptiste Duceau, Maxime Vignac, Guillaume Bonnet, Aurélie Carlier, Ronan Roussel, Antonin Trimaille, Thibaut Pommier, Pierre Guilleminot, Audrey Sagnard, Julie Pastier, Orianne Weizman, Gauthier Giordano, Joffrey Cellier, Laura Geneste, Vassili Panagides, Wassima Marsou, Antoine Deney, Clément Karsenty, Sabir Attou, Thomas Delmotte, Sophie Ribeyrolles, Pascale Chemaly, Alexandre Gautier, Charles Fauvel, Corentin Chaumont, Delphine Mika, Théo Pezel, Ariel Cohen, Louis Potier, on behalf of the Critical COVID-19 France Investigators
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.